Anlon Healthcare LimitedQuarter Ended 30-09-2026 Results & Financial Update
Anlon Healthcare Limited: Quarter Ended 30-09-2026 consolidated results and company financials – revenue ₹105.61 Cr, PAT ₹17.18 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Anlon Healthcare price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Anlon Healthcare Quarter Ended 30-09-2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Anlon Healthcare Limited delivered a substantial expansion in consolidated revenue and profitability for the second quarter of financial year 2027, propelled by robust demand across its API and drug intermediate portfolios.
Consolidated revenue from operations surged to INR 105.61 crore during the quarter ended September 30, 2026, marking an increase of over 102% compared to the corresponding period of the previous fiscal year and a sequential jump of 20.6% over the June 2026 quarter.
Total consolidated income reached INR 105.66 crore, supported by minor other income contributions of INR 0.05 crore, reflecting broad-based commercial traction across the group's manufacturing entities.
Profit before tax (PBT) for the quarter advanced to INR 23.47 crore, up 88.6% year-on-year and 71.8% sequentially, demonstrating strong operating leverage despite rising input costs.
Profit after tax (PAT) attributable to owners and non-controlling interests reached INR 17.18 crore, translating to an 84.4% year-on-year and 107.4% sequential increase. Earnings per share (EPS) for the quarter stood at INR 0.32, compared to INR 0.18 in the same quarter last year.
The five consolidated subsidiaries accounted for an aggregate total revenue of INR 53.20 crore (before consolidation adjustments) and a net profit after tax of INR 9.17 crore for the quarter ended September 30, 2026, underlining the growing earnings contribution from the broader corporate group.
01 · Business model
What does Anlon Healthcare do?
Anlon Healthcare Limited is a research-intensive manufacturing company headquartered in Rajkot, India, specializing in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates.
The company adheres to stringent international manufacturing standards and has earned global recognition for supplying bulk drugs to regulated and domestic markets.
The corporate structure includes several subsidiary entities—namely Bizotic Lifescience Private Limited, Apiqo Organics Private Limited, Anlon Medicos Private Limited, Anlon Biologics Private Limited, Anlon Medicare Private Limited, and Anlon Healthcare Nigeria Limited—which contribute to consolidated operations.
The company's equity shares are listed on both the National Stock Exchange of India (NSE) under the symbol AHCL and the Bombay Stock Exchange (BSE) under scrip code 544497 following its initial listing in September 2025.
02 · Historical context
What shaped the business before this quarter
The company's equity shares were listed on the National Stock Exchange of India and the Bombay Stock Exchange on September 3, 2025.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Quarter Ended 30-09-2026 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹105.61 Cr | ₹52.20 Cr | ₹87.56 Cr |
| Total income | ₹105.66 Cr | ₹52.23 Cr | ₹87.62 Cr |
| Profit before tax | ₹23.47 Cr | ₹12.45 Cr | ₹13.66 Cr |
| Profit after tax | ₹17.18 Cr | ₹9.32 Cr | ₹8.28 Cr |
| EPS | ₹0.32 | ₹0.18 | ₹0.16 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 16.3% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 22.2% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.05 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Strong demand for core Active Pharmaceutical Ingredients and drug intermediates drove operating revenue to INR 105.61 crore, representing a 102.3% year-on-year growth rate on a consolidated basis.
Consolidated performance benefited from the operational output of subsidiaries such as Apiqo Organics, Bizotic Lifescience, and Anlon Medicos, which collectively contributed INR 53.20 crore in pre-consolidation revenue.
What drove margins
Cost of materials consumed stood at INR 48.69 crore during the quarter, accompanied by inventory adjustments of INR 24.19 crore reflecting inventory buildup across manufacturing plants.
Employee benefit expenses were reported at INR 2.59 crore, while other expenses—comprising power, fuel, packing materials, factory electricity expenses, freight inward, advertisement, canteen, and import duty expenses—totaled INR 4.90 crore.
Finance costs for the quarter were contained at INR 0.86 crore, while depreciation and amortization expenses amounted to INR 0.95 crore, reflecting capital asset investments.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates and is reviewed by management as a single integrated business segment focused on the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) under Ind AS 108.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
Consolidated property, plant and equipment expanded to INR 78.53 crore as of September 30, 2026, up from INR 57.71 crore as of March 31, 2026, alongside capital work-in-progress of INR 1.36 crore.
07 · Reported developments
What changed operationally
Consolidated net profit after tax rose to INR 17.18 crore, marking an 84.4% year-on-year increase from INR 9.32 crore in the corresponding quarter of FY25.
08 · Pressure points & risks
What is not going smoothly
During the second quarter of FY27, the company received one complaint from an investor, which remained pending as of the reporting date.
09 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Trade receivables stood at INR 142.75 crore as of September 30, 2026, while inventories increased to INR 120.21 crore from INR 113.16 crore at March 31, 2026.
Capital allocation & funding
Consolidated borrowings as of September 30, 2026, included non-current borrowings of INR 10.62 crore and current borrowings of INR 61.67 crore.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Auditor Review
The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, were subjected to a limited review by statutory auditors R V D & Co.
11 · Previous-quarter changes
What changed since the previous quarter
Consolidated revenue from operations expanded by 20.6% sequentially from INR 87.56 crore in the quarter ended June 30, 2026, to INR 105.61 crore in the quarter ended September 30, 2026.
12 · Key Q&A
The quarter, answered directly
What does Anlon Healthcare do?
Anlon Healthcare Limited is a research-intensive manufacturing company headquartered in Rajkot, India, specializing in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates.
What is the clearest takeaway from Quarter Ended 30-09-2026?
Anlon Healthcare Limited delivered a substantial expansion in consolidated revenue and profitability for the second quarter of financial year 2027, propelled by robust demand across its API and drug intermediate portfolios.
What drove revenue or demand?
Strong demand for core Active Pharmaceutical Ingredients and drug intermediates drove operating revenue to INR 105.61 crore, representing a 102.3% year-on-year growth rate on a consolidated basis.
What mattered most for margins or profitability?
Cost of materials consumed stood at INR 48.69 crore during the quarter, accompanied by inventory adjustments of INR 24.19 crore reflecting inventory buildup across manufacturing plants.
What changed operationally beyond the headline numbers?
Consolidated property, plant and equipment expanded to INR 78.53 crore as of September 30, 2026, up from INR 57.71 crore as of March 31, 2026, alongside capital work-in-progress of INR 1.36 crore.
What are the main pressure points disclosed for the quarter?
During the second quarter of FY27, the company received one complaint from an investor, which remained pending as of the reporting date.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsidiary Integration: Monitor the ongoing financial contributions and operational integration of the company's five consolidated operating subsidiaries.
- 02
Capital Expenditure Progress: Track the commissioning of capital work-in-progress and the utilization of property, plant, and equipment additions.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.